Targeting HIFs [25] with drugs can hinder melanoma cell adaptation to hypoxia, reducing glycolytic enzyme and angiogenic factor upregulation, thereby weakening tumor survival in low‐oxygen environments and enhancing susceptibility to other treatments. Here, HK1 is linked to neoplasm.